Synthetic macromolecules as therapeutics that overcome resistance in cancer and microbial infection

Jason Tan,Joyce Tay,James Hedrick,Yi Yan Yang

DOI: https://doi.org/10.1016/j.biomaterials.2020.120078

IF: 14

2020-09-01

Biomaterials

Abstract:<p>Synthetic macromolecular antimicrobials have shown efficacy in the treatment of multidrug resistant (MDR) pathogens. These synthetic macromolecules, inspired by Nature's antimicrobial peptides (AMPs), mitigate resistance by disrupting microbial cell membrane or targeting multiple intracellular proteins or genes. Unlike AMPs, these polymers are less prone to degradation by proteases and are easier to synthesize on a large scale. Recently, various studies have revealed that cancer cell membrane, like that of microbes, is negatively charged, and AMPs can be used as anticancer agents. Nevertheless, efforts in developing polymers as anticancer agents has remained limited. This review highlights the recent advancement in the development of synthetic biodegradable antimicrobial polymers (e.g. polycarbonates, polyesters and polypeptides) and anticancer macromolecules including peptides and polymers. Additionally, strategies to improve their <em>in vivo</em> bioavailability and selectivity towards bacteria and cancer cells are examined. Lastly, future perspectives, including use of artificial intelligence or machine learning, in the development of antimicrobial and anticancer macromolecules are discussed.</p>

engineering, biomedical,materials science, biomaterials

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the challenge of multidrug resistance (MDR) in microbial infections and cancer treatment. Specifically:

1. **Multidrug Resistance in Microbial Infections**:
- The paper discusses the "discovery void" in current antibiotic discovery, which has led to a lack of new antibiotic classes to replace existing antibiotics that have become ineffective due to resistance.
- It specifically mentions that ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species) are the main causes of most nosocomial infections.
- It mentions new, multidrug - resistant fungal infections, such as Candida auris, which have increased resistance to major antifungal drugs and require new treatment strategies.

2. **Multidrug Resistance in Cancer Treatment**:
- Cancer is the second leading cause of death globally, causing approximately 9.6 million deaths each year.
- Multidrug resistance (MDR) is a major obstacle to the success of chemotherapy, leading to cancer recurrence and high mortality.
- It discusses multiple mechanisms that cause cancer cells to develop cross - resistance to drugs with different structures and functions, such as taxanes, anthracyclines, podophyllotoxins, antimetabolites, topotecan, actinomycin D, and mitomycin C.

3. **Solutions**:
- The paper explores the development of synthetic macromolecules as therapeutic agents, especially biodegradable polymers (such as polycarbonates, polyesters, and polypeptides) and anticancer macromolecules (including peptides and polymers).
- It emphasizes the potential of these synthetic macromolecules to overcome resistance by disrupting microbial cell membranes or targeting multiple intracellular proteins or genes.
- It discusses strategies to improve the in - vivo bioavailability and selectivity of these macromolecules, as well as the future prospects of using artificial intelligence or machine learning in the development of antibacterial and anticancer macromolecules.

In conclusion, this paper aims to propose new methods to overcome the problem of multidrug resistance in microbial infections and cancer treatment through synthetic macromolecule techniques, especially biodegradable polymers and anticancer macromolecules.